Nomograms for predicting pathological response to neoadjuvant treatments in patients with rectal cancer

Table 1 Predictive factors for complete pathological response in univariate logistic regression analysis for all patients

Variable		Non-pCR (n = 331) n P50 (P25-P75)	pCR (n = 72) n P50 (P25-P75)	pCR rate	P-value
Gender	Male	232	49	17.44%	0.653
	Female	96	23	19.33%
Age (yr)	≤ 60	210	54	20.45%	0.07
	> 60	119	18	13.14%
BMI (kg/cm2)	< 25	231	53	18.66%	0.581
	≥ 25	78	15	16.13%
Hemoglobin (g/L)	≤ 125	109	16	12.80%	0.126
	> 125	172	41	19.25%
NLR	> 3	37	11	22.92%	0.227
	≤ 3	244	46	15.86%
Platelet (× 109/L)		237.5 (200.25-286.75)	246 (200.5-268.5)		0.981
ApoA1 (g/L)		1.29 (1.13-1.44)	1.3 (1.15-1.52)		0.454
ApoB (g/L)		0.98 (0.79-1.14)	0.97 (0.82-1.19)		0.382
The interval (d)		39 (22.25-54)	50 (42-56.5)		0
CEA (ng/mL)	> 5	163	28	14.66%	0.217
	≤ 5	118	29	19.73%
Differentiation	Moderate-poor	274	44	13.84%	0.001
	Well	44	20	31.25%
DTAV (cm)	< 5	140	41	22.65%	0.024
	≥ 5	191	31	13.96%
TL (cm)	> 3	237	41	14.75%	0.001
	≤ 3	73	30	29.13%
TCE	< 50%	37	7	15.91%	0.772
	≥ 50%	256	55	17.68%
cT	2	16	5	23.81%	0.405
	3	234	56	19.31%
	4	54	8	12.90%
cN	+	235	57	19.52%	0.465
	-	78	15	16.13%
MRF	-	231	61	20.89%	0.013
	+	97	11	10.19%
NT regimen	Capecitabine/de Gramont-RT	102	13	11.30%	0
	mFOLFOX6	148	14	8.64%
	mFOLFOX6-RT	81	45	35.71%

Platelet, apolipoprotein A-1, apolipoprotein B, and the interval were calculated as metrological data, and others are counting data. pCR: Complete pathological response; NLR: Neutrophil-lymphocyte ratio; DTAV: Distance of tumor from the anal verge; TL: Tumor length; TCE: Tumor circumferential extent; NT: Neoadjuvant therapy; PLT: Platelet; ApoA1: Apolipoprotein A-1; ApoB: Apolipoprotein B; MRF: Mesorectal fascia; CEA: Carcinoembryonic antigen.